August 7, 2025Cancer ScienceOpen Access

BCL‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML

View Full Paper

Ask AI

Bookmark

Authors

XPXudong PengQingdao University YLYanhong LiDonghua University FTFutian TangLanzhou University Second Hospital

Discussion

Member takes

Implication

A study demonstrates that BCL-2 inhibitor Venetoclax improves T cell responses in AML, suggesting a role in antitumor immunity via glycolysis modulation.

Key Points

BCL-2 inhibitor Venetoclax significantly improves the activation and function of T cells in AML patients.
Venetoclax promotes T cell-mediated antitumor immune responses by enhancing cytokine secretion and T cell activation.
The research utilizes a PBMC-humanized AML mouse model to analyze T cell responses under the influence of Venetoclax.
Findings indicate a unique immune-dependent mechanism allowing molecular-targeted drugs to promote tumor cell death in AML.

Cite This Study

Peng et al. (2025) studied this question.

synapsesocial.com/papers/689dfe9fd61984b91e13c345 https://doi.org/10.1111/cas.70139

View Full Paper

Ask AI

Bookmark

Implication

A study demonstrates that BCL-2 inhibitor Venetoclax improves T cell responses in AML, suggesting a role in antitumor immunity via glycolysis modulation.

BCL‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML

Discussion

Member takes

Implication

Key Points

Cite This Study

BCL‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider